1,006
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Clinical characteristics of a patient with de novo acute promyelocytic leukemia with JAK2 v617f mutation

, , , , , , , & show all
Pages 1290-1293 | Received 09 Jun 2022, Accepted 24 Nov 2022, Published online: 07 Dec 2022

Figures & data

Figure 1. Morphologic features of BM sample from the patient. (A) BM aspiration smear on admission in February 2020 revealed abnormal accumulations of immature cells containing multiple Auer rods in the cytoplasm (arrow) (100×). (B) BM aspiration smear in November 2020 after APL CR revealed erythroid cells were significantly increased, mainly composed of middle and late juvenile erythrocytes. (arrow) (100×). (C) BM biopsy on admission in February 2020 showing hypercellularity of immature atypical myeloid cells (H&E-stained image, 40×). (D) BM biopsy in November 2020 after APL CR. H&E-stained sections show active hyperplasia of nucleated myeloid and erythroid cells. The morphology of those cells was generally normal (40×).

Figure 1. Morphologic features of BM sample from the patient. (A) BM aspiration smear on admission in February 2020 revealed abnormal accumulations of immature cells containing multiple Auer rods in the cytoplasm (arrow) (100×). (B) BM aspiration smear in November 2020 after APL CR revealed erythroid cells were significantly increased, mainly composed of middle and late juvenile erythrocytes. (arrow) (100×). (C) BM biopsy on admission in February 2020 showing hypercellularity of immature atypical myeloid cells (H&E-stained image, 40×). (D) BM biopsy in November 2020 after APL CR. H&E-stained sections show active hyperplasia of nucleated myeloid and erythroid cells. The morphology of those cells was generally normal (40×).

Figure 2. Clinical course of the patient. White blood counts (WBC), hemoglobin (Hb) and platelet (PLT) counts during the treatment. DS, differentiation syndrome; DA, daunorubicin + cytarabine; HA, harringtonine + cytarabine;

Figure 2. Clinical course of the patient. White blood counts (WBC), hemoglobin (Hb) and platelet (PLT) counts during the treatment. DS, differentiation syndrome; DA, daunorubicin + cytarabine; HA, harringtonine + cytarabine;